{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:39:21Z","timestamp":1793417961303,"version":"4.5.0"},"reference-count":46,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pusan National University Research Grant"},{"name":"Pusan National University Hospital"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: This study explores the association of neutrophil-to-lymphocyte (NLR), monocyte-to-lymphocyte (MLR), and platelet-to-lymphocyte (PLR) ratios with the 3-month treatment response and persistence of tumor necrosis factor-alpha (TNF-\u03b1) blockers in patients with ankylosing spondylitis (AS). Methods: This retrospective cohort study investigated 279 AS patients who were newly initiated on TNF-\u03b1 blockers between April 2004 and October 2019 and 171 sex- and age-matched healthy controls. Response to TNF-\u03b1 blockers was defined as a reduction in the Bath AS Disease Activity Index of \u226550% or 20 mm, and persistence referred to the time interval from the initiation to discontinuation of TNF-\u03b1 blockers. Results: Patients with AS had significantly increased NLR, MLR, and PLR ratios as compared to controls. The frequency of non-response at 3 months was 3.7%, and TNF-\u03b1 blockers\u2019 discontinuation occurred in 113 (40.5%) patients during the follow-up period. A high baseline NLR but not high baseline MLR and PLR showed an independently significant association with a higher risk of non-response at 3 months (OR = 12.3, p = 0.025) and non-persistence with TNF-\u03b1 blockers (HR = 1.66, p = 0.01). Conclusions: NLR may be a potential marker for predicting the clinical response and persistence of TNF-\u03b1 blockers in AS patients.<\/jats:p>","DOI":"10.3390\/ph16030379","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T02:10:59Z","timestamp":1677723059000},"page":"379","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis"],"prefix":"10.3390","volume":"16","author":[{"given":"Dong-Hyuk","family":"Moon","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan 49241, Republic of Korea"},{"name":"Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aran","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan 49241, Republic of Korea"},{"name":"Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Wook","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan 49241, Republic of Korea"},{"name":"Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0393-7264","authenticated-orcid":false,"given":"Yun-Kyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, College of Medicine, Kosin University, Busan 49104, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geun-Tae","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, College of Medicine, Kosin University, Busan 49104, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Young","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Pusan National University Yangsan Hospital, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Wook","family":"So","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Pusan National University Yangsan Hospital, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5205-3978","authenticated-orcid":false,"given":"Seung-Geun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan 49241, Republic of Korea"},{"name":"Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4078\/jrd.22.0023","article-title":"The Epidemiology and Treatment of Ankylosing Spondylitis in Korea","volume":"29","author":"Kwon","year":"2022","journal-title":"J. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nyas.13933","article-title":"Targeting tumor necrosis factor receptors in ankylosing spondylitis","volume":"1442","author":"Lata","year":"2019","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40259-020-00442-x","article-title":"Drug Survival of Biologics in Treating Ankylosing Spondylitis: A Systematic Review and Meta-analysis of Real-World Evidence","volume":"34","author":"Yu","year":"2020","journal-title":"BioDrugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14397595.2018.1564165","article-title":"Neutrophil lymphocyte ratio in patients with ankylosing spondylitis: A systematic review and meta-analysis","volume":"30","author":"Xu","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2174\/1573397117666210921114431","article-title":"A Systematic Review and Meta-analysis of Clinical Studies on Ankylosing Spondylitis and Neutrophil to Lymphocyte Ratio","volume":"18","author":"Khorrampazhouh","year":"2022","journal-title":"Curr. Rheumatol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00296-019-04276-x","article-title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as predictors of 12-week treatment response and drug persistence of anti-tumor necrosis factor-alpha agents in patients with rheumatoid arthritis: A retrospective chart review analysis","volume":"39","author":"Lee","year":"2019","journal-title":"Rheumatol. Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00296-020-04604-6","article-title":"Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as potential makers for digital ulcers and interstitial lung disease in patients with systemic sclerosis: Cross-sectional analysis of data from a prospective cohort study","volume":"40","author":"Kim","year":"2020","journal-title":"Rheumatol. Int."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Song, B.W., Kim, A.R., Moon, D.H., Kim, Y.K., Kim, G.T., Ahn, E.Y., So, M.W., and Lee, S.G. (2022). Associations of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio and Monocyte-to-Lymphocyte Ratio with Osteoporosis and Incident Vertebral Fracture in Postmenopausal Women with Rheumatoid Arthritis: A Single-Center Retrospective Cohort Study. Medicina, 58.","DOI":"10.3390\/medicina58070852"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Drugescu, A., Roca, M., Zota, I.M., Costache, A.D., Gavril, O.I., Gavril, R.S., Vasilcu, T.F., Mitu, O., Esanu, I.M., and Roca, I.C. (2022). Value of the Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Predicting CPET Performance in Patients with Stable CAD and Recent Elective PCI. Medicina, 58.","DOI":"10.3390\/medicina58060814"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hoppner, J., Casteleyn, V., Biesen, R., Rose, T., Windisch, W., Burmester, G.R., and Siegert, E. (2022). SIGLEC-1 in Systemic Sclerosis: A Useful Biomarker for Differential Diagnosis. Pharmaceuticals, 15.","DOI":"10.3390\/ph15101198"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1136\/annrheumdis-2018-213648","article-title":"Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis","volume":"77","author":"Soldano","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Eakin, A.J., Ahmed, T., McGeough, C.M., Drain, S., Alexander, H.D., Wright, G.D., Gardiner, P.V., Small, D., Bjourson, A.J., and Gibson, D.S. (2022). CD169+ Monocyte and Regulatory T Cell Subsets Are Associated with Disease Activity in Rheumatoid Arthritis. J. Pers. Med., 12.","DOI":"10.3390\/jpm12111875"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"722","DOI":"10.4149\/BLL_2015_142","article-title":"Neutrophil-to-lymphocyte ratio is involved in the severity of ankylosing spondylitis","volume":"116","author":"Kucuk","year":"2015","journal-title":"Bratisl. Med. J.-Bratisl. Lek. Listy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.5606\/ArchRheumatol.2016.5729","article-title":"Assessment of Neutrophil-Lymphocyte and Platelet- Lymphocyte Ratios in Ankylosing Spondylitis","volume":"31","author":"Boyraz","year":"2016","journal-title":"Arch. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s42358-020-0113-5","article-title":"Neutrophil\/lymphocyte and platelet\/lymphocyte ratios as potential markers of disease activity in patients with Ankylosing spondylitis: A case-control study","volume":"60","author":"Awadh","year":"2020","journal-title":"Adv. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.5152\/eurjrheumatol.2014.034","article-title":"Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti-tumor necrosis factor (TNF) drugs for ankylosing spondylitis","volume":"1","author":"Coskun","year":"2014","journal-title":"Eur. J. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"760214","DOI":"10.3389\/fimmu.2021.760214","article-title":"Platelet-to-Lymphocyte Ratio as an Independent Factor Was Associated With the Severity of Ankylosing Spondylitis","volume":"12","author":"Liang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1007\/s00405-016-3980-y","article-title":"Mean platelet volume, red cell distribution width, platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios in patients with ankylosing spondylitis and their relationships with high-frequency hearing thresholds","volume":"273","author":"Bozan","year":"2016","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/jcla.21768","article-title":"Neutrophil-Lymphocyte Ratio Connected to Treatment Options and Inflammation Markers of Ankylosing Spondylitis","volume":"29","author":"Gokmen","year":"2015","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.intimp.2018.02.008","article-title":"Relationship between monocytes to lymphocytes ratio and axial spondyloarthritis","volume":"57","author":"Huang","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"ref_22","first-page":"966","article-title":"Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: A literature review","volume":"26","author":"Ruof","year":"1999","journal-title":"J. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/rheumatology\/25.2.171","article-title":"Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis","volume":"25","author":"Sheehan","year":"1986","journal-title":"Br. J. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: A prospective longitudinal observational cohort study","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3904\/kjim.2016.042","article-title":"Drug survival of tumor necrosis factor alpha inhibitors in patients with ankylosing spondylitis in Korea","volume":"33","author":"Jeong","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10067-018-4324-7","article-title":"The persistence of golimumab compared to other tumour necrosis factor-alpha inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: Observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si","volume":"38","author":"Rotar","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lee, J.W., Kang, J.H., Yim, Y.R., Kim, J.E., Wen, L., Lee, K.E., Park, D.J., Kim, T.J., Park, Y.W., and Lee, S.S. (2015). Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0131864"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3346\/jkms.2014.29.9.1205","article-title":"Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"29","author":"Kang","year":"2014","journal-title":"J. Korean Med. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e000917","DOI":"10.1136\/rmdopen-2019-000917","article-title":"Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study","volume":"5","author":"Sieper","year":"2019","journal-title":"RMD Open"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/rheumatology\/keab565","article-title":"Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: Results from the DESIR cohort","volume":"61","author":"Sbidian","year":"2022","journal-title":"Rheumatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s42358-018-0040-x","article-title":"Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors","volume":"58","author":"Shimabuco","year":"2018","journal-title":"Adv. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3389\/fimmu.2019.00382","article-title":"Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses","volume":"10","author":"Menegatti","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3370","article-title":"Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response","volume":"13","author":"Appel","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10875-012-9774-0","article-title":"Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-alpha therapy","volume":"33","author":"Xueyi","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Martinez-Ramos, S., Rafael-Vidal, C., Pego-Reigosa, J.M., and Garcia, S. (2022). Monocytes and Macrophages in Spondyloarthritis: Functional Roles and Effects of Current Therapies. Cells, 11.","DOI":"10.3390\/cells11030515"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"Valkenburg","year":"1984","journal-title":"Arthritis Rheum."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/1756-185X.13917","article-title":"Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab","volume":"23","author":"Lee","year":"2020","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/tan.12186","article-title":"Epidemiological comparison of clinical manifestations according to HLA-B*27 carrier status of Chinese ankylosing spondylitis patients","volume":"82","author":"Yang","year":"2013","journal-title":"Tissue Antigens"},{"key":"ref_40","first-page":"2","article-title":"Classification of inflammatory bowel disease","volume":"170","year":"1989","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","article-title":"First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis","volume":"65","author":"Braun","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/phar.1856","article-title":"Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis","volume":"36","author":"Lee","year":"2016","journal-title":"Pharmacotherapy"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/acr.22944","article-title":"Persistence with Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans with Rheumatoid Arthritis","volume":"69","author":"Sauer","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Wilke, T., Mueller, S., Lee, S.C., Majer, I., and Heisen, M. (2017). Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: A retrospective non-interventional cohort analysis. BMC Musculoskelet. Disord., 18.","DOI":"10.1186\/s12891-017-1684-0"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/annrheumdis-2019-215427","article-title":"Treatment response and drug retention rates in 24 195 biologic-naive patients with axial spondyloarthritis initiating TNFi treatment: Routine care data from 12 registries in the EuroSpA collaboration","volume":"78","author":"Ornbjerg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1007\/s10067-020-05161-w","article-title":"Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: An 8-year retrospective cohort study","volume":"39","author":"Kim","year":"2020","journal-title":"Clin. Rheumatol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/3\/379\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:45:19Z","timestamp":1760121919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/3\/379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ph16030379"],"URL":"https:\/\/doi.org\/10.3390\/ph16030379","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}